Back to results
US 9,752,132 B2Granted
Engineered CRISPR-CAS9 nucleases with altered PAM specificity
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Benjamin Kleinstiver
Life of this patent
Estimating the term…
Abstract
Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
Claims24
An isolated variant Staphylococcus aureus Cas9 (SaCas9) protein comprising an amino sequence that has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 2, wherein the amino acid corresponding to E782 of SEQ ID NO:
- 2, the amino acid corresponding to N968 of SEQ ID NO:
- 2, and/or the amino acid corresponding to R1015 of SEQ ID NO:
- 2 is mutated in the variant SaCas9 protein, and wherein the variant SaCas9 protein binds to a guide RNA and a target DNA.
1 more element
Dependencies are inferred from the claim text.